GIP Receptor Agonist Peptides for Once-Weekly Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiemetic medications with GIP receptor agonist activity require frequent dosing, which can lead to poor patient compliance due to the frequency of administration, and there is a need for long-acting preparations that can effectively manage nausea and vomiting associated with various conditions.
Innovation Solution
Development of novel GIP receptor agonist peptide compounds with improved stability, half-life, and solubility, allowing for once-weekly dosing as a therapeutic agent for diabetes, obesity, and antiemetic treatment, specifically designed to activate GIP receptors and provide extended action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If frequent dosing is used for GIP receptor agonist antiemetic medications, then therapeutic effect is maintained, but patient compliance deteriorates
Solution Approach 1:
The patent modifies the peptide sequence parameters (amino acid sequence, molecular weight, hydrophobicity) to achieve extended half-life and once-weekly dosing. Specific modifications include altering the C-terminal sequence, adding specific amino acid residues, and adjusting the overall molecular structure to enhance stability and reduce degradation, thereby maintaining therapeutic effect with reduced dosing frequency and improved patient compliance.
2Ease of operation
If once-weekly dosing is implemented, then patient compliance improves, but duration of action must be extended
Solution Approach 1:
The patent changes peptide parameters including amino acid sequence, molecular weight, and structural configuration to extend the duration of action. Specific modifications involve altering the C-terminal region, adding stabilizing residues, and optimizing the peptide's interaction with GIP receptors to ensure sustained therapeutic activity over several weeks, enabling once-weekly administration.
Solution Approach 2:
The patent creates composite peptide structures combining multiple functional domains and modifications. The peptide comprises a core sequence with specific functional regions that bind to GIP receptors, plus additional modifications that enhance stability and extend half-life. This composite structure integrates receptor-binding functionality with stability-enhancing elements to achieve prolonged duration of action.
3Stability of the object's composition
If peptide stability in serum is improved, then half-life is extended, but solubility may be affected
Solution Approach 1:
The patent carefully adjusts peptide parameters including amino acid composition, molecular weight, and structural features to simultaneously achieve enhanced serum stability and maintained solubility. Specific modifications involve selecting amino acids that provide both stability and solubility, adjusting the peptide's charge distribution, and optimizing the C-terminal sequence to balance degradation resistance with aqueous solubility.
Data Source
AI summary
The present disclosure provides GIP receptor agonist peptide compounds suitable for once per week dosing (QW), said peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and/or prevention of emesis, or a symptom or condition associated with emesis. Specifically, a GIP receptor agonist peptide containing a sequence represented by any of the formulas (I)-(V) or a salt thereof, and a medicament comprising the same are provided.